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Background: There is a trend to cancel intrauterine insemination (IUI) in women with a high 
response. The aim of this study was to evaluate the efficacy of low-cost in vitro fertilization 
(IVF) in high-response IUI cycles in comparison with conventional IVF.
Methods and materials: A total of 46 women were included in the study. Group A (study 
group) included 23 women with hyper-response to IUI cycles who were converted to IVF. They 
received oral letrozole 2.5 mg twice daily from days 3–7 of the menstrual cycle, along with 75 
International Units (IU) of recombinant follicle-stimulating hormone on days 3 and 8. Group B 
(control group) underwent conventional IVF, and received downregulation with a gonadotrophin-
releasing hormone agonist followed by stimulation with recombinant follicle-stimulating 
hormone 150–300 IU/day. Ovulation was triggered by 10,000 IU of human chorionic gonado-
trophin, followed by IVF and embryo transfer. The primary outcome measure analyzed was 
pregnancy rates in both groups.
Results: The study group received a significantly lower (P = 0.001) total dose of follicle-
stimulating hormone and had significantly (P = 0.002) decreased levels of terminal estradiol. 
Although the pregnancy rate (30.43% in the study group versus 39.13% in the conventional 
group) per stimulated cycle was higher in the conventional IVF group, the miscarriage rate 
(study group 4.34% versus conventional group 13.04%) was also higher, and hence the take-
home baby rate (study group 26.08% versus conventional group 30.43%) was more or less 
similar in both the groups.
Conclusion: IVF can be offered to women having a high response to IUI cycles with good 
pregnancy rates and at low cost compared with use of a conventional protocol, and therefore 
can be considered more patient-friendly in selected cases.
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Introduction
Since the birth of the first in vitro fertilization (IVF) baby almost 30 years ago,   dramatic 
developments have occurred in assisted reproductive technology. The approach of 
maximizing pregnancy rates per cycle has led to very complex and costly ovarian 
hyperstimulation protocols. Ovarian stimulation has been applied with the aim of 
increasing the number of oocytes in order to compensate for inefficiencies of the IVF 
procedure, enabling the selection of one or more embryos for transfer.1 In the context 
of improved laboratory performance, the need for a large number of oocytes as an 
integral part of a successful IVF program may be questioned.
Currently used medication regimens for ovarian stimulation are complex, expen-
sive, may require weeks of daily injections, and intense ovarian response monitoring Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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is usually needed. Such regimens are associated with the 
risk of complications, such as ovarian hyperstimulation 
syndrome2–4 and impaired luteal phase. Other negative effects 
associated with ovarian stimulation include emotional stress, 
high dropout rates, and abdominal discomfort.1 Moreover, 
uncertainties remain regarding long-term health risks (such 
as ovarian cancer) and an increased incidence of low birth 
weight and birth defects in the offspring conceived following 
IVF treatment.5–8 Some investigators suggest poor embryo 
quality and chromosomal abnormalities associated with 
  ovarian stimulation.9,10 In contrast with current approaches, 
mild ovarian stimulation for IVF intends to limit the number 
of oocytes obtained to fewer than eight,11,12 with an accept-
able pregnancy rate.
In 1996, Edwards et al were the first to express concern 
with regard to contemporary ovarian stimulation approaches 
for IVF and called for the use of a milder stimulation 
  protocol.13 The aim of mild stimulation is to develop safer 
and more patient-friendly protocols in which the risks of 
treatment are minimized.2,6,11,14–17
The term “low-cost IVF” was coined by Professor Alan 
Trounson at a World Health Organization meeting in Geneva 
in 2001. The concern of the World Health Organization had 
always been to promote advances in health care in low-
resource economies. A milder stimulation protocol offers 
the same advantages as natural-cycle IVF, but has higher 
efficacy by recruiting one dominant follicle in addition to a 
few codominant follicles that do not develop spontaneously 
in a natural cycle.2,18 However, there are reservations about 
the efficacy of a low-dose approach, including lower preg-
nancy rates compared with conventional IVF, in addition to 
a lower profit for IVF centers. In some cases when undergo-
ing intrauterine insemination (IUI), taking 75 International 
Units (IU) of human menopausal gonadotrophin will result 
in a high response with many follicles developing leading 
to subsequent cancellation for fear of multiple pregnancy or 
severe ovarian hyperstimulation syndrome. The aim of the 
present study was to evaluate the efficacy of rescue IVF in 
high-response IUI cycles (ie, low-cost IVF) compared with 
a conventional protocol.
Materials and methods
selection of participants
The study was performed at King Abdel Aziz University 
Hospital between October 2008 and April 2010. Approval 
by the research ethics board of the institution was obtained, 
and written consent was obtained from all patients after 
  careful counseling. During the study period, we had 
46 women scheduled for IUI and those having a high response 
were recruited for the study. All these women underwent both 
ultrasound and endocrine assessment prior to the beginning 
of treatment. Those patients who had previously failed IVF 
or had previous laparotomy were excluded from the study. 
Patients with moderate to severe endometriosis and a baseline 
follicle-stimulating hormone level $12 mIU/mL were also 
excluded. Twenty-three women with hyper-response in IUI 
cycles who subsequently underwent IVF were included in the 
study group (Group A). Twenty-three women with similar 
demographic and endocrine characteristics during the same 
period were randomly selected, excluding any bias, and 
were included in the control group (Group B) to undergo 
conventional IVF.
As in traditional ovarian stimulation for IUI, women 
in Group A received oral letrozole (Letroz®, Sun Pharma-
ceuticals, Mumbai, India) at a dose of 2.5 mg twice daily 
from days 3–7 of the menstrual cycle, and recombinant 
follicle-stimulating hormone (Gonal-F®, Serono, Aubonne, 
Switzerland) was administered subcutaneously at a dose of 
75 IU/day on days 3 and 8 of the menstrual cycle. The dose 
was subsequently adjusted according to the response.
Women in Group B received the conventional protocol 
for controlled ovarian hyperstimulation, ie, a daily subcutane-
ous 500 µg injection of a gonadotrophin-releasing hormone 
(GnRH) agonist, leuprolide acetate (Lupride4®, Sun Phar-
maceuticals, Mumbai, India) starting from the mid-luteal 
phase of the previous cycle and continuing for a period of 
14 days, or until the onset of the next menstruation, which-
ever was earlier. If the patient did not start menstruating by 
day 14 of GnRH agonist treatment, estradiol and leutiniz-
ing hormone levels were assayed and analyzed. Estradiol 
levels #10 pg/mL or leutinizing hormone #3 mIU/mL were 
considered to be evidence of downregulation. If the patient 
did not meet these criteria, the GnRH agonist was continued 
for a further four days at the same dose. Recombinant follicle-
stimulating hormone was administered subcutaneously to 
the downregulated subjects at a dose of 100–150 IU/day, 
with subsequent adjustment of the dose according to the 
dose-response scheme.
All patients were monitored for ovarian follicular devel-
opment by transvaginal ultrasonography. When the average 
diameter of the lead follicle(s) reached $18 mm, blood was 
drawn for assessment of terminal estradiol, and the women 
were administered 10,000 IU human chorionic gonadotro-
phin (Pregnyl®, Organon, The Netherlands) subcutaneously Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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as a single dose. Oocytes were retrieved by transvaginal 
ultrasonography 34–36 hours after administration of human 
chorionic gonadotrophin. The retrieved oocytes were 
  inseminated with spermatozoa from the husband. Embryo 
transfer was performed 40–42 hours following insemination 
at the 4–6-cell cleavage stage. All patients received 600 mg 
micronized progesterone (Utrogestan®, Laboratories Besins 
International, Paris, France) intravaginally daily until a 
pregnancy test was performed, and, if the test was positive, 
progesterone treatment was continued up to gestational 
week 12. Clinical pregnancy was defined when an ultrasound 
scan, performed five weeks after embryo transfer, revealed 
the presence of a viable fetus.
immunoassay of hormones
Serum levels of leutinizing hormone and follicle-stimulating 
hormone were measured by a two-site chemiluminescent 
sandwich immunoassay system (ACS 180, Bayer Diagnostics 
Corporation, Tarrytown, NY). All samples were assayed in 
duplicate. The leutinizing hormone and follicle-stimulating 
hormone values were expressed in terms of the World 
Health Organization reference standards. Assay sensitivity 
for follicle-stimulating hormone was 0.3 mIU/mL and for 
leutinizing hormone was 0.07 mIU/mL. Estradiol levels were 
assayed by a fully automated enzyme-linked fluorescence 
assay system (Vidas®, BioMerieux, Marcy-l’Etoile, France). 
The minimum detection limit was 9 pg/mL. The intra-assay 
and inter-assay coefficients of variation were 3.46% and 
4.82% for follicle-stimulating hormone; 4.4% and 5.6% 
for leutinizing hormone; and 4.2% and 5.2% for estradiol, 
respectively. The primary outcome measure was pregnancy 
outcome, while additional measures included total dose of 
follicle-stimulating hormone administered, number of mature 
follicles, levels of terminal estradiol, number of oocytes 
retrieved, endometrial thickness, and transferable embryos.
statistics
Statistical comparisons were performed using the Student’s 
t-test and X2-test (v 17: SPSS), as applicable. P , 0.05 was 
considered to be statistically significant.
Results
All patients were euthyroid and normoprolactinemic and 
both groups were comparable with respect to all baseline 
clinical and demographic characteristics (Table 1). The 
composite results of treatment outcome are summarized 
in Table 2. Compared with the conventional group, the 
low-cost IVF patients received a much lower total dose of 
follicle-stimulating hormone and had significantly decreased 
levels of terminal estradiol. However, the two groups did not 
differ significantly with respect to the number of matured fol-
licles or endometrial thickness. The number of transferable 
embryos was significantly lower in the low-cost IVF group 
than in the conventional group. There were no dropouts from 
either group. One stimulated cycle (4.34%) in the low-cost 
group was cancelled due to poor ovarian response (emergence 
of no dominant follicle). In the conventional group, three 
women had ovarian hyperstimulation (Table 3). Although 
the pregnancy rate per stimulated cycle was higher in the 
conventional IVF group, the miscarriage rate was also higher, 
and hence the take-home baby rate was more or less similar 
in both the groups (Table 4).
Discussion
Natural cycle IVF and modified natural cycle IVF with use 
of a GnRH antagonist are cheaper modalities of low-cost 
IVF. However, their usage is limited by high cancellation 
rates. Mild stimulation indicates lower doses and fewer 
days of gonadotrophin administration combined with oral 
drugs (clomiphene citrate or aromatase inhibitors). This 
appears to be less complex but with improved compliance. 
The success of aromatase inhibition by letrozole in 
inducing ovulation in anovulatory women with polycystic 
ovarian syndrome19 and augmenting ovulation in ovulatory 
women19,20 has been reported previously. It has also 
been shown that, when   letrozole is used with follicle-
stimulating hormone, a   significant reduction occurs in the 
follicle-stimulating   hormone dose needed for controlled 
ovarian hyperstimulation.20 The successful use of letro-
zole in increasing ovarian   sensitivity to gonadotrophins 
and inducing superovulation prompted us to utilize the 
same in reducing the cost of IVF by significant reduction 
of gonadotrophin dosage. Most of the studies undertaken to 
evaluate the efficacy of low-cost IVF used a combination of 
clomiphene citrate and gonadotrophins.21–25
There is little information about the use of aromatase 
inhibitors for IVF because the number of series published 
in the literature is small and the majority of studies are 
  nonrandomized. In a prospective randomized pilot study, 
Verpoest et al26 showed that response to controlled ovarian 
stimulation improved with the use of aromatase inhibitors. In 
normal responders undergoing an ovarian stimulation proto-
col, women were randomized to receive recombinant follicle-
stimulating hormone 150 IU and a GnRH antagonist with Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Baseline demographic and clinical characteristics of subjects treated with low-cost iVF and conventional iVF protocols
Group* Age (years) 
mean ± SD
Body mass 
index (kg/m2)
Basal FSH 
(U/L)
Basal leutinizing 
hormone (U/L)
Estradiol 
(pg/mL)
Low-cost iVF 
(n = 23)
28.78 ± 4.9 26.2 ± 3.1 5.48 ± 1.29 6.37 ± 3.25 34.46 ± 16.62
conventional iVF  
(n = 23)
29.48 ± 3.04 26.8 ± 3.6 5.72 ± 1.82 6.07 ± 2.4 45.31 ± 15.48
Note: *All patients were euthyroid and normoprolactinemic. 
Abbreviations: iVF, in vitro fertilization; FsH, follicle-stimulating hormone.
Table 2 Treatment outcomes in women in low-cost iVF and conventional iVF groups
Outcome Low-cost IVF Conventional  P value
Total dose of FsH (iU) 1195.65 ± 609.61 2168.48 ± 985.87 0.001
number of mature follicles 6.26 ± 2.83 6.83 ± 3.33 0.539
estradiol (pg/mL) 1775.68 ± 683.04 2692.61 ± 1101.12 0.002
Transferred embryos 4.50 ± 2.40 7.61 ± 4.24 0.004
endometrial thickness 10.35 ± 2.42 9.90 ± 1.61 0.457
Note: Values are mean ± sD. 
Abbreviations: FsH, follicle-stimulating hormone; iVF, in vitro fertilization.
letrozole 2.5 mg/day during the first five days of stimulation 
versus no letrozole. A higher number of oocytes retrieved per 
cycle was documented in the letrozole group (14.8 versus 9.6), 
although the difference was not statistically significant. 
Pregnancy outcome was similar in both study groups. 
A similar result was also observed in the present study due 
to no significant difference between the two groups.
Goswami et al27 reported the first randomized controlled 
trial to assess whether incorporation of letrozole could be 
an effective low-cost IVF protocol for poor responders. 
Women over 35 years of age, who had failed 1–3 previous 
IVF attempts due to poor ovarian response to a conventional 
long GnRH agonist stimulation protocol were selected for 
this study. A total of 13 participants were randomized to 
letrozole 2.5 mg/day for days 3–7 of the menstrual cycle 
and subcutaneous recombinant follicle-stimulating hor-
mone at a dose of 75 IU/day on days 3 and 8, while the 
remaining 25 participants underwent a long GnRH agonist 
protocol and were stimulated with recombinant follicle-
stimulating hormone 300–450 IU/day (controls). Compared 
with the control group, the letrozole-recombinant follicle-
stimulating group received a significantly lower total dose 
of follicle-stimulating hormone and had significantly 
decreased levels of terminal estradiol. The two groups did 
not differ with respect to the numbers of matured follicles, 
retrieved oocytes, transferable embryos, or endometrial 
thickness. The pregnancy rate per stimulated cycle was 
also similar. The authors concluded that adjunctive use 
of letrozole may be an effective low-cost IVF protocol in 
poorly responding women.
Garcia-Velasco et al28 evaluated the use of letrozole as 
an adjuvant to follicle-stimulating treatment in IVF cycles of 
poor responders. To be included in the study, patients had to 
have at least one previously cancelled IVF attempt in which 
four or fewer follicles 16 mm in diameter were obtained. 
Women were divided into a control group of 76 patients 
treated with high-dose gonadotrophins in a GnRH antagonist 
regimen, whereas the experimental group of 71 patients 
received letrozole 2.5 mg plus gonadotrophins for the first 
5 days of stimulation followed by the same GnRH antagonist 
regimen. The number of oocytes retrieved, intrafollicular 
levels of androgens, and implantation rates were significantly 
higher among the letrozole-treated patients. Pregnancy rates 
were also higher, but the differences were not statistically 
significant.
Schoolcraft et al29 have recently reported the results of 
a comparison of the efficacy of a microdose GnRH agonist 
flare with a GnRH antagonist-letrozole protocol before IVF 
embryo transfer in poor responders. There were no differ-
ences in duration or dose of gonadotrophins required, days 
of stimulation, numbers of oocytes, percentage of mature 
oocytes obtained, fertilization rate, and embryo quality. 
However, ongoing pregnancy rates were significantly lower 
on the letrozole protocol than on the microdose GnRH agonist 
flare protocol (37% versus 52%).
Due to the selective inhibition of aromatase, letrozole 
significantly inhibits the overall production of estrogens. 
Consequent withdrawal of the negative feedback effects of 
estrogens may allow the pituitary to produce more endog-
enous follicle-stimulating hormone. Moreover,   attenuated Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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compared with a conventional protocol, and can   therefore, be 
considered more patient-friendly in selected cases.
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In conclusion, IVF can be offered to women with high-
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